Approved comparison material connected to this topic.
11 total recordsSource comparisons are presented without a generated winner.
Aged mice (preclinical, J Neuroscience 2021) 1mg/kg 16 weeks Hippocampal neurogenesis (BrdU+ cells) +35% Sustained neurogenesis observed only with chronic dosing. Intermittent protocols showed no benefit Prima…
| Protocol | Dose | Frequency | Duration Studied | VAT Reduction (vs Baseline) | Glucose Impact | Clinical Context ||—|—|—|—|—|—|| FDA-Approved (Egrifta) | 2mg SC | Daily | 26–52 weeks | −15.2% at 26 weeks | M…
1mg SC daily 8.2% (95% CI: 6.1–10.3%) 22% discontinuation due to AEs Subtherapeutic. Not recommended 2mg SC daily (bedtime) 15.6% (95% CI: 13.2–18.0%) 28% discontinuation due to AEs FDA-approved standard. Prov…
2mg SC daily (fasted, pre-bed) 15–18% +1–2% 8–12 Phase 3 RCTs (n>800) Gold standard. Only protocol with reproducible VAT reduction without lean mass loss 1mg SC daily 5–7% No significant change 4–6 Observation…
Tesamorelin 2mg daily GHRH analogue → GH secretion → VAT lipolysis 31–37% in VAT+ patients VAT >1600 cm³ required Off-label (approved for HIV lipodystrophy) Most effective in visceral-adiposity-driven NASH; re…
HIV-Associated Lipodystrophy (FDA-Approved) 2mg daily Once daily, evening Sterile water for injection IGF-1 every 8 weeks, visceral adipose tissue via CT or MRI every 12-16 weeks Ongoing (discontinue if no VAT…
The table below compares tesamorelin dosing protocols based on clinical trial data, practical administration factors, and VAT reduction outcomes. Standard Clinical 2mg SC daily Evening (8-10 PM) 15-18% mean re…
EGRIFTA-1 (Lancet 2010) 2mg daily SC 26 weeks 15.2% vs 4.9% placebo 32% (mostly injection site reactions) Gold standard. Establishes 2mg as optimal dose with significant VAT reduction and acceptable safety pro…
2mg SC daily (standard) 15.2% mean reduction 30% injection site reactions, 12% arthralgia FDA-approved for HIV lipodystrophy First-line therapy. Established efficacy and safety profile 1mg SC daily (reduced) 8…
Standard FDA-Approved 2mg SC Evening (within 2h of bedtime) 15–20% mean reduction +6–9 mg/dL fasting glucose Patients with baseline HbA1c <6.0%, no insulin resistance Gold standard. Maximizes VAT loss with acc…
1mg daily Once daily subcutaneous 5–8% VAT reduction Minimal. Occasional injection site erythema Investigational only; insufficient for clinical VAT targets Below therapeutic threshold. Detectable GH pulse but…